Thu 12/13/2018 12:37 ET
S&P 5002648.122.910.11%BANKS400.303.920.98%OIL51.900.751.45%BITCOIN3412.8371.332.09%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Penny Stocks (Lexaria Bioscience - LXRP)   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add LXRP
From: NetworkNewsWire (Rep: 0)Date: 01/11/2018 18:37
Forum: Penny Stocks - Msg #1153 - List LXRP msgs Thread #673981771 (Rec: 0)
2017 was a Transformative Year for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

- Lexaria’s CEO posts end of 2017 summary
- Multiple transformative developments – IP strengthened, broad patents awarded, finances secured
- Foundation for the future established – multiple opportunities on horizon

If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future.

Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible products. Already scientifically proven to enhance absorption of orally ingested cannabinoids, Lexaria’s novel drug delivery platform is believed to be applicable across a wide range of different vitamins, drug types and cannabinoids, dramatically impacting bio-absorption and bioavailability, as well as taste, smell and speed of action.

Lexaria’s DehydraTECH™ technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers, and it can be used with both patented and generic pharmaceutical substances. This breakthrough plays into Lexaria’s long term strategy to partner with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery more predictable, safer and more effective.

The first item addressed in the CEO summary was company finances. With a commitment to enhancing shareholder value, Lexaria cleaned up its balance sheet, raised well over $4 million and paid off all its debt. With cash in the bank, the company announced a $1 million budget for R&D using its patented DehydraTECH™ absorption and palatability-enhancing technology to create even more long term value. The company continued multiple absorption tests and formulation experiments, and it continues to pursue a number of intellectual property (IP) enhancement procedures to expand its IP portfolio.

The most significant and transformational developments of 2017 centered on the incredible value created with Lexaria’s intellectual properties. Late in 2016, Lexaria received its first U.S. patent award. Then, in the first half of 2017, the company received its first patent award in Australia. Lexaria announced in November that it had received a broad ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent includes all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. Lexaria is continuing to advance all of its 33 other patent applications pending around the world. The impact of these patents not only creates value and validates Lexaria’s technology; it also opens untold avenues of business opportunity, some of which may be realized over the course of the coming year.

Lexaria has also taken large positions in subsidiary companies that could benefit from the global liberalization of cannabis. Lexaria owns 50 percent of Ambarii Trade Corp., which may offer international opportunities for a class of mouth-melt consumer products delivered with Lexaria’s technology. Lexaria consolidated ownership of PoViva Tea LLC and now own 100 percent. The company also successfully introduced TurboCBD™, a 100 percent-owned brand of hemp oil empowered with DehydraTECH™.

The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit opportunities in the Canadian cannabinoid products sector.

As the abundance of good news from last year begins to sink in, it certainly appears that Lexaria is making all the right moves to make 2018 even better.

For more information, visit the company’s website at

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser NetworkNewsWire: Reward | Watch | IgnoreLXRP: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add LXRP | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.